PSA (prostate specific antigen) tests to be reimbursed in Germany
This article was originally published in Clinica
Executive Summary
A decision by the German Upper House (Bundesrat) to approve prostate specific antigen (PSA) tests, used to diagnose prostate cancer, for reimbursement by the statutory health insurance funds, has been welcomed by the diagnostics industry association, VDGH. "This is the first concrete indication of politicians paying more than lip service to promises that the early detection of illness should play a more important role in the health service," said VDGH chairman Dierk Meyer-Luerbetaen.